The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia.

Gutjahr, JC; Greil, R; Hartmann, TN; Front Immunol. 2015; 6:177

Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia.

Kern, D; Regl, G; Hofbauer, SW; Altenhofer, P; Achatz, G; Dlugosz, A; Schnidar, H; Greil, R; Hartmann, TN; Aberger, F; Oncogene. 2015; 34(42):534-551

CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms.

Hutterer, E; Asslaber, D; Caldana, C; Krenn, PW; Zucchetto, A; Gattei, V; Greil, R; Hartmann, TN; Br J Haematol. 2015; 169(2):286-289

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.

Them, NC; Bagienski, K; Berg, T; Gisslinger, B; Schalling, M; Chen, D; Buxhofer-Ausch, V; Thaler, J; Schloegl, E; Gastl, GA; Wolf, D; Strecker, K; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Zagrijtschuk, O; Klade, C; Greil, R; Gisslinger, H; Kralovics, R; Am J Hematol. 2015; 90(4):288-294

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin“s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.

Behringer, K; Goergen, H; Hitz, F; Zijlstra, JM; Greil, R; Markova, J; Sasse, S; Fuchs, M; Topp, MS; Soekler, M; Mathas, S; Meissner, J; Wilhelm, M; Koch, P; Lindemann, HW; Schalk, E; Semrau, R; Kriz, J; Vieler, T; Bentz, M; Lange, E; Mahlberg, R; Hassler, A; Vogelhuber, M; Hahn, D; Mezger, J; Krause, SW; Skoetz, N; Böll, B; von Tresckow, B; Diehl, V; Hallek, M; Borchmann, P; Stein, H; Eich, H; Engert, A; Lancet. 2015; 385(9976):1418-1427

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.

Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Knauer, M; Moik, M; Jakesz, R; Seifert, M; Taucher, S; Bjelic-Radisic, V; Balic, M; Eidtmann, H; Eiermann, W; Steger, G; Kwasny, W; Dubsky, P; Selim, U; Fitzal, F; Hochreiner, G; Wette, V; Sevelda, P; Ploner, F; Bartsch, R; Fesl, C; Greil, R; Ann Oncol. 2015; 26(2):313-320

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

Robak, T; Huang, H; Jin, J; Zhu, J; Liu, T; Samoilova, O; Pylypenko, H; Verhoef, G; Siritanaratkul, N; Osmanov, E; Alexeeva, J; Pereira, J; Drach, J; Mayer, J; Hong, X; Okamoto, R; Pei, L; Rooney, B; van de Velde, H; Cavalli, F; N Engl J Med. 2015; 372(10): 944-953.

IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer–results of a case series after 5-year follow-up.

Fastner, G; Reitsamer, R; Ziegler, I; Zehentmayr, F; Fussl, C; Kopp, P; Peintinger, F; Greil, R; Fischer, T; Deutschmann, H; Sedlmayer, F; Int J Cancer. 2015; 136(5):1193-1201

Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.

Pircher, M; Mlineritsch, B; Fridrik, MA; Dittrich, C; Lang, A; Petru, E; Weltermann, A; Thaler, J; Hufnagl, C; Gampenrieder, SP; Rinnerthaler, G; Ressler, S; Ulmer, H; Greil, R; Anticancer Res. 2015; 35(1):517-521

A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?

Schlick, K; Troch, M; Placher-Sorko, G; Faber, V; Neureiter, D; Berghoff, AS; Preusser, M; Greil, R; Hopfinger, G; Ann Hematol. 2015; 94(2):345-346